ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IMNM vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY

Immunome Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: IMNM 1 — MRK 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: IMNM
balance-sheet
25.03
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMNM VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IMNM MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -9.29% 3.42% -12.71 MRK /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin -60.00% 28.10% -88.10 MRK /net-margins <GO>
Revenue Growth (YoY) -23.20% 1.30% -24.50 MRK /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 25.03 5.19 +19.84 IMNM /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 51.7 -11.50 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.16B $361.02B -$358.86B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IMNM REV MRK REV IMNM GROSS % MRK GROSS % IMNM FCF MRK FCF
FY 2025 $6.9M $65.01B — 74.8% -$200.6M $12.36B
FY 2024 $9.0M $64.17B — 76.3% -$118.0M $18.10B
FY 2023 $14.0M $60.12B — — -$7.6M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMNM // BETA —
MRK // BETA 0.92